By Nick Paul Taylor
Arcutis Biotherapeutics has spent the weeks since the FDA approval of its topical plaque psoriasis cream Zoryve strengthening its cash position, drawing down $125 million from its loan facility and raising $162 million via a stock offering. That done, the biotech has launched the PDE4 inhibitor in the U.S.
read more
By Nick Paul Taylor
Versant Ventures has committed $30 million to improve gene delivery. By pumping the cash into Vector BioPharma, the VC is aiming to address the limitations of existing systems such as the cap on the size of the genetic cargo.
read more
By Nick Paul Taylor
West Pharmaceutical Services is throwing its weight behind intradermal delivery technology, making a strategic investment in the developer of a low-cost approach to the rapid, consistent dosing of vaccines and biologics via the skin.
read more
By Teresa Carey
This week on "The Top Line," we explore what the landmark drug pricing bill that passed in the Senate means for the industry. We also chat about Pfizer's latest buy and what it suggests for M&A trends.
read more
Sponsored by: Thermo Fisher Scientific
Set a solid foundation for successful scale-up of buffer preparation.
Sponsored by: Triangle Insights Group, LLC
The TrialCard/Triangle Insights Group platform is uniquely positioned to support you as your asset progresses through the value chain, by integrating strategic commercialization and market access insights with comprehensive patient and provider support services.
Sponsored by: Thermo Fisher Scientific
See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead.
Sponsored by: Catalent
What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations?
Sponsored by: Catalent
Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.
Sponsored by: Catalent
What are key considerations for intranasal delivery in the treatment of acute and chronic conditions?
Sponsored by: Catalent
Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound.
Sponsored by: Catalent
How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market?
Sponsored by: Catalent
Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry.
Sponsored by: Catalent
Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays?
Sponsored by: Catalent
Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar.
